Table 2.
Summary of clinical trials of Picrorhiza kurruoa (alone) and Picrorhiza kurroa in combination with other agents in liver related and other disorders.
| Formulation and Study Design | Dose | Duration and No of subjects | Adversity | Activity | Reference |
|---|---|---|---|---|---|
| Arogyavardhini &Punarnavadi (Open label) | 500 mg x 3 & 30 ml x 2 |
3 weeks N = 24 |
No ADR | Acute Viral Hepatitis | [57] |
| Arogyavardhini (Double Blind) | 750 mg x 3 | 2 weeks N = 20 |
No ADR | Acute Viral Hepatitis | [58] |
| Kutaki (Double Blind) | 375 mg x 3 | 2 weeks N = 15 |
No ADR | Acute Viral Hepatitis | [15] |
| Kutaki + Methoxasalen (Oral & Topical) | 200 mg x 2 20 mg once |
3months N = 30 |
No ADR | Vitiligo | [59] |
| Kutaki with Sita (Two arms) | One gm x 2 | 3 weeks N = 30 (15 in each group) |
No ADR | Amlapitta | [60] |
| Arogyavardhini &Triphala Guggulu and Pathya (Two arms) | 250 mg x 2 | 3months N = 21 |
No ADR | NAFLD | [61] |
| Phalatrikadi Kwath (Open Label) | 40 ml x 2 | 6months N = 59 |
No ADR | HbsAg + ve | [62] |
| Kutaki processed in Guduchi with Atorvastatin (Open Label) |
Atovarstatin: 20 mg twice daily+2 gm Katukai (P. Kurroa) processed in Guduchi twice daily | 3months N = 32 |
No ADR | Hepatoprotective | [63] |
| Elastographic liver evaluation of Katukyadi churna in the management of Non-Alcoholic Steatohepatitis (NASH) – A single arm clinical trial | 6 gm (Sachets) twice a day with water. Katukyadichurna comprises 1 part each of Katuki + Nimba + Amrita + Bhringaraj + Bhumyamalki |
180 days | 11 patients participated in the study. Two patients suffered from loose stools 2–3 times/day for the first 8 days. | NASH | [64] |